A Phase 1/2 Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Glanzmann Thrombasthenia

Glanzmann Thrombasthenia Clinical Trial

Official title:
A Phase 1/2, First-in-Human, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Participants With Glanzmann Thrombasthenia

Status Recruiting

Clinical Trial Summary

The goal of this clinical trial is to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Participants with Glanzmann Thrombasthenia. The main questions it aims to answer are: - Parts A, B, and C: To determine the safety and tolerability of HMB-001 - Part A: To establish the dose level(s) and dosing interval(s) of HMB-001 to be investigated in Parts B and C - Parts B and C: To estimate the ability of HMB-001 to prevent the number and severity of bleeds Part A will assess differing singular doses of HMB-001 in small groups of participants. The dose administered to a newly enrolled participant (or groups of participants) may only increase if analysis of data from previous dosing shows it is safe to do so. The planned duration of participation in Part A is approximately 6 months, which consists of a Screening Period, an optional Run-in Observation Period, and a follow-up period of 8 weeks. Part B is similar to Part A as it involves testing different dose levels of HMB-001 in small groups of participants. However, in Part B, HMB-001 is given multiple times over a 3-month period, either weekly, every 2 weeks, or every 4 weeks. Part B consists of a Screening Period, a Run-in Observation Period, a 3-month Treatment Period, and a Safety Follow-up following the last dose of HMB-001. Part C is open to participants from Part B and consists of approximately a 9-month Treatment Period and a Safety Follow-up following the last dose of HMB-001.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Glanzmann Thrombasthenia

Clinical Trial Details

NCT number	NCT06211634
Study type	Interventional
Source	Hemab ApS
Contact	Catherine Rea
Phone	+44 0808 304 6409
Email	clinicaltrials@hemab.com
Status	Recruiting
Phase	Phase 1/Phase 2
Start date	December 13, 2022
Completion date	February 28, 2026

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT01319851` - Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation	N/A
Recruiting	`NCT00230165` - The Genetics and Functional Basis of Inherited Platelet, White Blood Cell, Red Blood Cell, and Blood Clotting Disorders.
Recruiting	`NCT02179359` - Hematopoietic Stem Cell Transplant for High Risk Hemoglobinopathies	N/A
Recruiting	`NCT04119908` - Videomicroscopy for the Prediction of Bleeding in Constitutional Haemorrhagic Diseases	N/A
Terminated	`NCT04548791` - Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Inherited Bleeding Disorders	Phase 1/Phase 2
Not yet recruiting	`NCT06204042` - Multinational Glanzmann Study
Completed	`NCT04595617` - Anti-αIIbβ3 Immunization in Glanzmann Thrombasthenia: Prevalence and Associated Risk Factors: Thrombasthenia Anti-αIIbβ3 Antibodies Study (TAAS)	N/A
Completed	`NCT01917708` - Bone Marrow Transplant With Abatacept for Non-Malignant Diseases	Phase 1
Active, not recruiting	`NCT03333486` - Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer	Phase 2
Completed	`NCT06234813` - Targeting TFPI With Concizumab to Improve Haemostasis in Glanzmann Thrombasthenia Patients: an in Vitro Study	N/A
Completed	`NCT05315232` - The Experiences of People Who Live With Glanzmanns Thrombasthenia.